BioCryst Pharmaceuticals Total Assets | BCRX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets BioCryst Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
514 M	490 M	517 M	550 M	588 M	335 M	175 M	147 M	178 M	89.8 M	125 M	137 M	48.9 M	57.4 M	82.2 M	109 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
588 M	48.9 M	259 M

Quarterly Total Assets BioCryst Pharmaceuticals

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
558 M	465 M	446 M	457 M	480 M	490 M	491 M	472 M	468 M	517 M	523 M	530 M	510 M	550 M	559 M	-	528 M	588 M	266 M	277 M	284 M	335 M	335 M	335 M	335 M	175 M	175 M	175 M	175 M	147 M	147 M	147 M	147 M	178 M	178 M	178 M	178 M	89.8 M	89.8 M	89.8 M	89.8 M	122 M	122 M	122 M	122 M	137 M	137 M	137 M	137 M	48.9 M	48.9 M	48.9 M	48.9 M	57.4 M	57.4 M	57.4 M	57.4 M	82.2 M	82.2 M	82.2 M	82.2 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
588 M	48.9 M	249 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Aclaris Therapeutics ACRS	160 M	$ 5.71	7.24 %	$ 700 M	USA
Фармсинтез LIFE	2.05 B	-	-	-	Russia
AbbVie ABBV	134 B	$ 261.51	1.66 %	$ 463 B	USA
AbCellera Biologics ABCL	1.36 B	$ 11.09	1.84 %	$ 3.31 B	Canada
Agenus AGEN	227 M	$ 7.16	3.17 %	$ 213 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	816 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	64.4 M	-	-14.46 %	$ 27.9 M	USA
ASLAN Pharmaceuticals Limited ASLN	24.6 M	-	-14.27 %	$ 1.7 M	Singapore
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adaptimmune Therapeutics plc ADAP	246 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Abeona Therapeutics ABEO	220 M	$ 5.39	0.28 %	$ 285 M	USA
Agios Pharmaceuticals AGIO	1.3 B	$ 33.38	0.16 %	$ 1.94 B	USA
Adagene ADAG	78.3 M	$ 3.29	2.94 %	$ 194 M	China
iTeos Therapeutics ITOS	687 M	-	-	$ 411 M	USA
Galmed Pharmaceuticals Ltd. GLMD	18.6 M	$ 4.63	21.05 %	$ 20 M	Israel
Adaptive Biotechnologies Corporation ADPT	513 M	$ 24.82	2.56 %	$ 3.77 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
BioXcel Therapeutics BTAI	44.9 M	$ 0.07	9.81 %	$ 855 K	USA
Allakos ALLK	96.6 M	-	-	$ 28.6 M	USA
Cyclerion Therapeutics CYCN	8.5 M	$ 23.52	458.67 %	$ 98.9 M	USA
MediWound Ltd. MDWD	31.1 M	$ 13.84	5.57 %	$ 377 M	Israel
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	380 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	94.6 M	$ 5.12	0.1 %	$ 981 M	Canada
ADC Therapeutics SA ADCT	323 M	$ 1.11	3.76 %	$ 141 M	Schweiz
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
Adial Pharmaceuticals ADIL	6.67 M	$ 4.97	1.43 %	$ 3.32 M	USA
ACADIA Pharmaceuticals ACAD	1.56 B	$ 27.48	0.04 %	$ 4.63 B	USA
AIM ImmunoTech AIM	5.78 M	$ 0.22	0.05 %	$ 356 K	USA
ADMA Biologics ADMA	624 M	$ 9.15	0.16 %	$ 2.18 B	USA
Axcella Health AXLA	18.9 M	-	-16.42 %	$ 249 M	USA
SQZ Biotechnologies Company SQZ	99.9 M	-	57.95 %	$ 12.8 M	USA
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
Achieve Life Sciences ACHV	41.8 M	$ 7.28	3.12 %	$ 317 M	USA
Baudax Bio BXRX	10 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	28.7 M	-	-10.95 %	$ 876 K	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
Codiak BioSciences CDAK	172 M	-	-55.98 %	$ 2.15 M	USA
ChemoCentryx CCXI	426 M	-	-	$ 3.74 B	USA
Akebia Therapeutics AKBA	377 M	$ 0.98	3.01 %	$ 252 M	USA
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
Cerevel Therapeutics Holdings CERE	1.24 B	-	-	$ 7.29 B	USA
AC Immune SA ACIU	154 M	$ 2.67	2.6 %	$ 269 M	Schweiz
Alector ALEC	293 M	$ 2.22	3.74 %	$ 229 M	USA